1420-04-8
1420-04-8
Chemical Structure
Niclosamide olamine
Synonym(s): BAY2353 olamine
- CAS No.: 1420-04-8
- Formula:C15H15Cl2N3O5
- Molecular Weight:388.20
IUPAC Name: 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide compound with 2-aminoethan-1-ol (1:1)
InChIKey: XYCDHXSQODHSLG-UHFFFAOYSA-N
SMILES: O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O.NCCO
Biological Activity: Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide olamin is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Niclosamide olamine | 98.66% | Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research. Niclosamide olamin is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells. Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Niclosamide olamine (Standard) | ≥98% | Niclosamide olamine (Standard) (BAY2353 olamine (Standard)) is the analytical standard of Niclosamide olamine (HY-B0497C). This product is intended for research and analytical applications. Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research. Niclosamide olamin is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells. Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95. [Content Brief]
- [2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96. [Content Brief]
- [3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66. [Content Brief]
- [4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9. [Content Brief]
- [5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. [Content Brief]
